Cancer-associated target protein

Cancer-associated target protein refers to a broad and heterogeneous class of molecules that are critically involved in the initiation, progression, and survival of various malignancies. This category encompasses a wide range of protein types, including cell-surface receptors such as the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), intracellular signaling enzymes like AKT1 and PI3K, and regulators of apoptosis such as BCL-2 [1, 6, 9, 10]. In oncogenic states, these proteins often exhibit genetic alterations, including mutations, gene amplifications, or chromosomal translocations, which lead to constitutive activity and the promotion of uncontrolled cell growth and evasion of programmed cell death [2, 6, 9]. Therapeutic strategies targeting these molecules utilize various modalities, including small-molecule inhibitors, monoclonal antibodies, and RNA-interference-based technologies [3, 8, 10, 11]. The identification and characterization of these proteins are central to precision oncology, enabling the development of targeted therapies that aim for higher specificity and reduced systemic side effects compared to traditional cytotoxic treatments [2, 3, 5]. However, the clinical effectiveness of these therapies is often challenged by biological heterogeneity, the emergence of resistance mechanisms, and the critical need for robust biomarkers to guide patient selection [1, 5, 10].

Other names

Cancer target proteinsOncogenic target proteinsTumor-associated proteinsMalignancy-associated targets

Targeting involves varied mechanisms such as tyrosine kinase inhibition, competitive antagonism of receptors, immune checkpoint blockade, and induction of apoptotic pathways [3, 6, 9].